X0306 4 2017-06-26 0 0001269021 PORTOLA PHARMACEUTICALS INC PTLA 0001574589 Curnutte John T C/O PORTOLA PHARMACEUTICALS, INC. 270 EAST GRAND AVE. SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Executive Vice President Common Stock 2017-06-26 4 M 0 60000 8.50 A 60000 D Common Stock 2017-06-26 4 S 0 6159 55.47 D 53841 D Common Stock 2017-06-26 4 S 0 11356 56.71 D 42485 D Common Stock 2017-06-26 4 S 0 10729 57.24 D 31756 D Common Stock 2017-06-26 4 S 0 17954 58.35 D 13802 D Common Stock 2017-06-26 4 S 0 3802 59.33 D 10000 D Common Stock 2017-06-26 4 S 0 10000 60.00 D 0 D Stock Option (Right to Buy) 8.50 2017-06-26 4 M 0 60000 0.00 D 2011-03-23 2021-03-23 Common Stock 60000 11918 D The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2017. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.98 to $55.94, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (6) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.00 to $56.99, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (6) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.00 to $57.96, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (6) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.00 to $58.97, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (6) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.00 to $59.96, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (6) to this Form 4. /s/ Mike Ouimette, as attorney-in-fact 2017-06-28